An evaluation of roflumilast and PDE4 inhibitors with a focus on the treatment of asthma

References

• O’Byrne PM. Evolving concepts in asthma. Semin Respir Crit Care Med. 2018;39(1):1–2.
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Naji N, Gauvreau GM. Severe asthma: future treatments. Clin Exp Allergy. 2012;42(5):706–711.
   PubMed Web of Science ®Google Scholar
• Hirota N, Martin JG. Mechanisms of airway remodeling. Chest. 2013;144(3):1026–1032.
   PubMed Web of Science ®Google Scholar
• Brightling CE. Chronic obstructive pulmonary disease phenotypes, biomarkers, and prognostic indicators. Allergy Asthma Proc. 2016;37(6):432–438.
   PubMed Web of Science ®Google Scholar
• Papi A, Brightling C, Pedersen SE, et al. Asthma. Lancet. 2018;391(10122):783–800.
   PubMed Web of Science ®Google Scholar
• Clark AR. Anti-inflammatory functions of glucocorticoid-induced genes. Mol Cell Endocrinol. 2007;275(1–2):79–97.
   PubMed Web of Science ®Google Scholar
• Ray A, Oriss TB, Wenzel SE. Emerging molecular phenotypes of asthma. Am J Physiol Lung Cell Mol Physiol. 2015;308(2):L130–140.
   PubMed Web of Science ®Google Scholar
• Castro M, Wenzel SE, Bleecker ER, et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014;2(11):879–890.
   PubMed Web of Science ®Google Scholar
• Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–366.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141.
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, O’Byrne PM, Boulet LP, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014;370(22):2102–2110.
   PubMed Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–2496.
   PubMed Web of Science ®Google Scholar
• Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936–946.
   PubMed Web of Science ®Google Scholar
• Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31–44.
   PubMed Web of Science ®Google Scholar
• Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360(10):985–993.
   PubMed Web of Science ®Google Scholar
• Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007;176(11):1062–1071.
   PubMed Web of Science ®Google Scholar
• Menzella F, Piro R, Facciolongo N, et al. Long-term benefits of omalizumab in a patient with severe non-allergic asthma. Allergy Asthma Clin Immunol. 2011;7(1):9.
   PubMedGoogle Scholar
• Baines KJ, Simpson JL, Wood LG, et al. Sputum gene expression signature of 6 biomarkers discriminates asthma inflammatory phenotypes. J Allergy Clin Immunol. 2014;133(4):997–1007.
   PubMed Web of Science ®Google Scholar
• Gibson PG, Simpson JL, Saltos N. Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest. 2001;119(5):1329–1336.
   PubMed Web of Science ®Google Scholar
• Fukakusa M, Bergeron C, Tulic MK, et al. Oral corticosteroids decrease eosinophil and CC chemokine expression but increase neutrophil, IL-8, and IFN-gamma-inducible protein 10 expression in asthmatic airway mucosa. J Allergy Clin Immunol. 2005;115(2):280–286.
   PubMed Web of Science ®Google Scholar
• Busse WW, Holgate S, Kerwin E, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 2013;188(11):1294–1302.
   PubMed Web of Science ®Google Scholar
• Nair P, Gaga M, Zervas E, et al. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin Exp Allergy. 2012;42(7):1097–1103.
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Metev H, Puu M, et al. Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2016;4(10):797–806.
   PubMed Web of Science ®Google Scholar
• Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther. 2006;109(3):366–398.
   PubMed Web of Science ®Google Scholar
• Nicholson CD. Cyclic nucleotide phosphodiesterase isoenzymes and asthma–outstanding issues. Agents Actions Suppl. 1993;43:3–12.
   PubMedGoogle Scholar
• Barnes PJ. Cyclic nucleotides and phosphodiesterases and airway function. Eur Respir J. 1995;8(3):457–462.
   PubMed Web of Science ®Google Scholar
• Gantner F, Tenor H, Gekeler V, et al. Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: a comparative study. J Allergy Clin Immunol. 1997;100(4):527–535.
   PubMed Web of Science ®Google Scholar
• Martin-Chouly CA, Astier A, Jacob C, et al. Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors. Life Sci. 2004;75(7):823–840.
   PubMed Web of Science ®Google Scholar
• Billington CK, Joseph SK, Swan C, et al. Modulation of human airway smooth muscle proliferation by type 3 phosphodiesterase inhibition. Am J Physiol. 1999;276(3 Pt 1):L412–419.
   PubMedGoogle Scholar
• Souness JE, Griffin M, Maslen C, et al. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a ‘low-affinity’ phosphodiesterase 4 conformer. Br J Pharmacol. 1996;118(3):649–658.
   PubMed Web of Science ®Google Scholar
• Oger S, Méhats C, Dallot E, et al. Evidence for a role of phosphodiesterase 4 in lipopolysaccharide-stimulated prostaglandin E2 production and matrix metalloproteinase-9 activity in human amniochorionic membranes. J Immunol. 2005;174(12):8082–8089.
   PubMed Web of Science ®Google Scholar
• Ogawa Y, Duru EA, Ameredes BT. Role of IL-10 in the resolution of airway inflammation. Curr Mol Med. 2008;8(5):437–445.
   PubMed Web of Science ®Google Scholar
• Murphy DM, Ward C, Forrest IA, et al. The phosphodiesterase type IV inhibitor cilomilast decreases pro-inflammatory cytokine production from primary bronchial epithelial cells in lung transplantation patients. J Heart Lung Transplant. 2006;25(12):1436–1440.
   PubMed Web of Science ®Google Scholar
• Selige J, Hatzelmann A, Dunkern T. The differential impact of PDE4 subtypes in human lung fibroblasts on cytokine-induced proliferation and myofibroblast conversion. J Cell Physiol. 2011;226(8):1970–1980.
   PubMed Web of Science ®Google Scholar
• Blease K, Burke-Gaffney A, Hellewell PG. Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4. Br J Pharmacol. 1998;124(1):229–237.
   PubMed Web of Science ®Google Scholar
• Billington CK, Le Jeune IR, Young KW, et al. A major functional role for phosphodiesterase 4D5 in human airway smooth muscle cells. Am J Respir Cell Mol Biol. 2008;38(1):1–7.
   PubMed Web of Science ®Google Scholar
• Giembycz MA. Development status of second generation PDE4 inhibitors for asthma and COPD: the story so far. Monaldi Arch Chest Dis. 2002;57(1):48–64.
   PubMedGoogle Scholar
• Barber R, Baillie GS, Bergmann R, et al. Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. Am J Physiol Lung Cell Mol Physiol. 2004;287(2):L332–343.
   PubMed Web of Science ®Google Scholar
• Kung TT, Crawley Y, Luo B, et al. Inhibition of pulmonary eosinophilia and airway hyperresponsiveness in allergic mice by rolipram: involvement of endogenously released corticosterone and catecholamines. Br J Pharmacol. 2000;130(2):457–463.
   PubMed Web of Science ®Google Scholar
• Kanehiro A, Ikemura T, Mäkelä MJ, et al. Inhibition of phosphodiesterase 4 attenuates airway hyperresponsiveness and airway inflammation in a model of secondary allergen challenge. Am J Respir Crit Care Med. 2001;163(1):173–184.
   PubMed Web of Science ®Google Scholar
• Kumar RK, Herbert C, Thomas PS, et al. Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma. J Pharmacol Exp Ther. 2003;307(1):349–355.
   PubMed Web of Science ®Google Scholar
• Wang P, Myers JG, Wu P, et al. Expression, purification, and characterization of human cAMP-specific phosphodiesterase (PDE4) subtypes A, B, C, and D. Biochem Biophys Res Commun. 1997;234(2):320–324.
   PubMed Web of Science ®Google Scholar
• Pérez-Torres S, Miró X, Palacios JM, et al. Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and[3H]rolipram binding autoradiography: comparison with monkey and rat brain. J Chem Neuroanat. 2000;20(3–4):349–374.
   PubMed Web of Science ®Google Scholar
• Card GL, England BP, Suzuki Y, et al. Structural basis for the activity of drugs that inhibit phosphodiesterases. Structure. 2004;12(12):2233–2247.
   PubMed Web of Science ®Google Scholar
• Reid P. Roflumilast altana pharma. Curr Opin Invest Drugs. 2002;3(8):1165–1170.
   PubMedGoogle Scholar
• Kwak HJ, Song JS, Heo JY, et al. Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation. J Pharmacol Exp Ther. 2005;315(3):1188–1195.
   PubMed Web of Science ®Google Scholar
• Peachell PT, Undem BJ, Schleimer RP, et al. Preliminary identification and role of phosphodiesterase isozymes in human basophils. J Immunol. 1992;148(8):2503–2510.
   PubMed Web of Science ®Google Scholar
• Buenestado A, Grassin-Delyle S, Guitard F, et al. Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide. Br J Pharmacol. 2012;165(6):1877–1890.
   PubMed Web of Science ®Google Scholar
• Sousa LP, Lopes F, Silva DM, et al. PDE4 inhibition drives resolution of neutrophilic inflammation by inducing apoptosis in a PKA-PI3K/Akt-dependent and NF-kappaB-independent manner. J Leukoc Biol. 2010;87(5):895–904.
   PubMed Web of Science ®Google Scholar
• Sanz MJ, Cortijo J, Taha MA, et al. Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability. Br J Pharmacol. 2007;152(4):481–492.
   PubMed Web of Science ®Google Scholar
• Jones NA, Boswell-Smith V, Lever R, et al. The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro. Pulm Pharmacol Ther. 2005;18(2):93–101.
   PubMed Web of Science ®Google Scholar
• Southworth T, Kaur M, Hodgson L, et al. Anti-inflammatory effects of the phosphodiesterase type 4 inhibitor CHF6001 on bronchoalveolar lavage lymphocytes from asthma patients. Cytokine. 2018;113:68–73.
   PubMed Web of Science ®Google Scholar
• Tenor H, Hatzelmann A, Church MK, et al. Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects. Br J Pharmacol. 1996;118(7):1727–1735.
   PubMed Web of Science ®Google Scholar
• Liu J, Muñoz NM, Meliton AY, et al. Beta2-integrin adhesion caused by eotaxin but not IL-5 is blocked by PDE-4 inhibition and beta2-adrenoceptor activation in human eosinophils. Pulm Pharmacol Ther. 2004;17(2):73–79.
   PubMed Web of Science ®Google Scholar
• Dent G, Giembycz MA, Evans PM, et al. Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol. J Pharmacol Exp Ther. 1994;271(3):1167–1174.
   PubMed Web of Science ®Google Scholar
• Eskandari N, Wickramasinghe T, Peachell PT. Effects of phosphodiesterase inhibitors on interleukin-4 and interleukin-13 generation from human basophils. Br J Pharmacol. 2004;142(8):1265–1272.
   PubMed Web of Science ®Google Scholar
• Eskandari N, Bastan R, Peachell PT. Regulation of human skin mast cell histamine release by PDE inhibitors. Allergol Immunopathol (Madr). 2015;43(1):37–41.
   PubMed Web of Science ®Google Scholar
• Peachell PT, MacGlashan DW, Lichtenstein LM, et al. Regulation of human basophil and lung mast cell function by cyclic adenosine monophosphate. J Immunol. 1988;140(2):571–579.
   PubMed Web of Science ®Google Scholar
• Komatsu K, Lee JY, Miyata M, et al. Inhibition of PDE4B suppresses inflammation by increasing expression of the deubiquitinase CYLD. Nat Commun. 2013;4:1684.
   PubMed Web of Science ®Google Scholar
• Hohlfeld JM, Schoenfeld K, Lavae-Mokhtari M, et al. Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trial. Pulm Pharmacol Ther. 2008;21(4):616–623.
   PubMed Web of Science ®Google Scholar
• Gamble E, Grootendorst DC, Brightling CE, et al. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;168(8):976–982.
   PubMed Web of Science ®Google Scholar
• Grootendorst DC, Gauw SA, Baan R, et al. Does a single dose of the phosphodiesterase 4 inhibitor, cilomilast (15 mg), induce bronchodilation in patients with chronic obstructive pulmonary disease? Pulm Pharmacol Ther. 2003;16(2):115–120.
   PubMed Web of Science ®Google Scholar
• Grootendorst DC, Gauw SA, Benschop N, et al. Efficacy of the novel phosphodiesterase-4 inhibitor BAY 19-8004 on lung function and airway inflammation in asthma and chronic obstructive pulmonary disease (COPD). Pulm Pharmacol Ther. 2003;16(6):341–347.
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Chervinsky P, Busse W, et al. Roflumilast for asthma: efficacy findings in placebo-controlled studies. Pulm Pharmacol Ther. 2015;35(Supp l):S20–27.
   PubMedGoogle Scholar
• Bateman ED, Izquierdo JL, Harnest U, et al. Efficacy and safety of roflumilast in the treatment of asthma. Ann Allergy Asthma Immunol. 2006;96(5):679–686.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Aubier M, Sastre J, et al. Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma. Allergy. 2006;61(1):72–78.
   PubMed Web of Science ®Google Scholar
• Albrecht A, Leichtl S, Bredenbröker D, et al. A new orally active, selective phosphodiesterase 4 inhibitor, with beclomethasone propionate in asthma control. Eur Respir J. 2002;20:304s.
   Google Scholar
• Leichtl S, Schmid-Wirlitsch C, Bredenbröker D, et al. Roflumilast, a new orally active, selective phosphodiesterase 4 inhibitor is effective in the treatment of asthma. Eur Respir J. 2002;20:304S.
   Google Scholar
• Lu S, Liu N, Dass SB, et al. Randomized, placebo-controlled study of a selective PDE4 inhibitor in the treatment of asthma. Respir Med. 2009;103(3):342–347.
   PubMed Web of Science ®Google Scholar
• Luo J, Yang L, Yang J, et al. Efficacy and safety of phosphodiesterase 4 inhibitors in patients with asthma: a systematic review and meta-analysis. Respirology. 2018;23(5):467–477.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Goehring UM, Richard F, et al. Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma. J Allergy Clin Immunol. 2016;138(1):142–149.e148.
   PubMed Web of Science ®Google Scholar
• Bardin P, Kanniess F, Gauvreau G, et al. Roflumilast for asthma: efficacy findings in mechanism of action studies. Pulm Pharmacol Ther. 2015;35(Suppl):S4–10.
   PubMedGoogle Scholar
• Louw C, Williams Z, Venter L, et al. Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after allergen challenge. Respiration. 2007;74(4):411–417.
   PubMed Web of Science ®Google Scholar
• van Schalkwyk E, Strydom K, Williams Z, et al. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J Allergy Clin Immunol. 2005;116(2):292–298.
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, Boulet LP, Schmid-Wirlitsch C, et al. Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects. Respir Res. 2011;12:140.
   PubMed Web of Science ®Google Scholar
• Singh D, Leaker B, Boyce M, et al. A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients. Pulm Pharmacol Ther. 2016;40:1–6.
   PubMed Web of Science ®Google Scholar
• Leaker BR, Singh D, Ali FY, et al. The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma. BMC Pulm Med. 2014;14:166.
   PubMed Web of Science ®Google Scholar
• Timmer W, Leclerc V, Birraux G, et al. The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo. J Clin Pharmacol. 2002;42(3):297–303.
   PubMed Web of Science ®Google Scholar
• Chervinsky P, Meltzer EO, Busse W, et al. Roflumilast for asthma: safety findings from a pooled analysis of ten clinical studies. Pulm Pharmacol Ther. 2015;35(Suppl):S28–34.
   PubMedGoogle Scholar
• Yan JH, Gu WJ, Pan L. Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysis. Pulm Pharmacol Ther. 2014;27(1):83–89.
   PubMed Web of Science ®Google Scholar
• Postma DS, Rabe KF. The asthma-COPD overlap syndrome. N Engl J Med. 2015;373(13):1241–1249.
   PubMed Web of Science ®Google Scholar
• Alshabanat A, Zafari Z, Albanyan O, et al. Asthma and COPD overlap syndrome (ACOS): a systematic review and meta analysis. PLoS One. 2015;10(9):e0136065.
   PubMed Web of Science ®Google Scholar
• Isajevs S, Taivans I, Svirina D, et al. Patterns of inflammatory responses in large and small airways in smokers with and without chronic obstructive pulmonary disease. Respiration. 2011;81(5):362–371.
   PubMed Web of Science ®Google Scholar
• Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet. 2004;364(9435):709–721.
   PubMed Web of Science ®Google Scholar
• Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(26):2645–2653.
   PubMed Web of Science ®Google Scholar
• Lapperre TS, Willems LN, Timens W, et al. Small airways dysfunction and neutrophilic inflammation in bronchial biopsies and BAL in COPD. Chest. 2007;131(1):53–59.
   PubMed Web of Science ®Google Scholar
• Boulet LP, Boulay M, Dérival JL, et al. Asthma-COPD overlap phenotypes and smoking: comparativefeatures of asthma in smoking or non-smoking patients with an incomplete reversibility of airway obstruction. COPD. 2018;15(2):130–138.
   PubMedGoogle Scholar
• Alotaibi NM, Chen V, Hollander Z, et al. Phenotyping COPD exacerbations using imaging and blood-based biomarkers. Int J Chron Obstruct Pulmon Dis. 2018;13:217–229.
   PubMed Web of Science ®Google Scholar
• Burgel PR, Paillasseur JL, Janssens W, et al. A simple algorithm for the identification of clinical COPD phenotypes. Eur Respir J. 2017;50(5). pii: 1701034.
   Web of Science ®Google Scholar
• Rennard SI, Locantore N, Delafont B, et al. Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. Ann Am Thorac Soc. 2015;12(3):303–312.
   PubMed Web of Science ®Google Scholar
• Saha S, Brightling CE. Eosinophilic airway inflammation in COPD. Int J Chron Obstruct Pulmon Dis. 2006;1(1):39–47.
   PubMedGoogle Scholar
• Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320(7245):1297–1303.
   PubMed Web of Science ®Google Scholar
• Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361(9356):449–456.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003;22(6):912–919.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009;374(9691):685–694.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Eriksson G, Jenkins CR, et al. Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:13–25.
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnacle H, Birk R, et al. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(4):438–446.
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680.
   PubMed Web of Science ®Google Scholar
• Halpin DMG, Birk R, Brealey N, et al. Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses. ERJ Open Res. 2018;4(2).
   PubMedGoogle Scholar
• Chapman KR, Hurst JR, Frent SM, et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in copd patients (sunset): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med. 2018;198(3):329–339.
   Web of Science ®Google Scholar
• Bateman ED, Rabe KF, Calverley PM, et al. Roflumilast with long-acting β2-agonists for COPD: influence of exacerbation history. Eur Respir J. 2011;38(3):553–560.
   PubMed Web of Science ®Google Scholar
• Rennard SI, Calverley PM, Goehring UM, et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast–the importance of defining different subsets of patients with COPD. Respir Res. 2011;12:18.
   PubMed Web of Science ®Google Scholar
• Facius A, Marostica E, Gardiner P, et al. Pharmacodynamic modelling to characterize the tolerability of alternative up-titration regimens of roflumilast in patients with chronic obstructive pulmonary disease. Clin Pharmacokinet. 2018;57(8):1029–1038.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Calverley PM, Goehring UM, et al. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015;385(9971):857–866.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Rabe KF, Sethi S, et al. Effect of roflumilast and inhaled corticosteroid/long-acting β2-agonist on chronic obstructive pulmonary disease exacerbations (re(2)spond): a randomized clinical trial. Am J Respir Crit Care Med. 2016;194(5):559–567.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Rabe KF, Calverley PMA, et al. Determinants of response to roflumilast in severe COPD: pooled analysis of two randomized trials. Am J Respir Crit Care Med. 2018.
   Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Calverley PMA, Albert RK, et al. Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2017;50(3). pii: 1602265.
   Web of Science ®Google Scholar
• Grootendorst DC, Gauw SA, Verhoosel RM, et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax. 2007;62(12):1081–1087.
   PubMed Web of Science ®Google Scholar
• Grundy S, Plumb J, Kaur M, et al. Additive anti-inflammatory effects of corticosteroids and phosphodiesterase-4 inhibitors in COPD CD8 cells. Respir Res. 2016;17:9.
   PubMed Web of Science ®Google Scholar
• Muñoz-Esquerre M, Diez-Ferrer M, Montón C, et al. Roflumilast added to triple therapy in patients with severe COPD: a real life study. Pulm Pharmacol Ther. 2015;30:16–21.
   PubMed Web of Science ®Google Scholar
• Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009;374(9691):695–703.
   PubMed Web of Science ®Google Scholar
• O’Donnell DE, Bredenbröker D, Brose M, et al. Physiological effects of roflumilast at rest and during exercise in COPD. Eur Respir J. 2012;39(5):1104–1112.
   PubMed Web of Science ®Google Scholar
• Myou S, Fujimura M, Kamio Y, et al. Bronchodilator effect of inhaled olprinone, a phosphodiesterase 3 inhibitor, in asthmatic patients. Am J Respir Crit Care Med. 1999;160(3):817–820.
   PubMed Web of Science ®Google Scholar
• Myou S, Fujimura M, Kamio Y, et al. Bronchodilator effects of intravenous olprinone, a phosphodiesterase 3 inhibitor, with and without aminophylline in asthmatic patients. Br J Clin Pharmacol. 2003;55(4):341–346.
   PubMed Web of Science ®Google Scholar
• Zuo H, Han B, Poppinga WJ, et al. Cigarette smoke up-regulates PDE3 and PDE4 to decrease cAMP in airway cells. Br J Pharmacol. 2018;175(14):2988–3006.
   PubMed Web of Science ®Google Scholar
• Venkatasamy R, Spina D. Novel relaxant effects of RPL554 on guinea pig tracheal smooth muscle contractility. Br J Pharmacol. 2016;173(15):2335–2351.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Page CP, Spina D, et al. Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. J Pharmacol Exp Ther. 2013;346(3):414–423.
   PubMed Web of Science ®Google Scholar
• Franciosi LG, Diamant Z, Banner KH, et al. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respir Med. 2013;1(9):714–727.
   PubMed Web of Science ®Google Scholar
• Turner MJ, Matthes E, Billet A, et al. The dual phosphodiesterase 3 and 4 inhibitor RPL554 stimulates CFTR and ciliary beating in primary cultures of bronchial epithelia. Am J Physiol Lung Cell Mol Physiol. 2016;310(1):L59–70.
   PubMed Web of Science ®Google Scholar
• Boulet LP, Gauvreau G, Boulay ME, et al. Clinical investigative collaboration CnNoCoEA. The allergen bronchoprovocation model: an important tool for the investigation of new asthma anti-inflammatory therapies. Allergy. 2007;62(10):1101–1110.
   PubMedGoogle Scholar
• Gauvreau GM, Doctor J, Watson RM, et al. Effects of inhaled budesonide on allergen-induced airway responses and airway inflammation. Am J Respir Crit Care Med. 1996;154(5):1267–1271.
   PubMed Web of Science ®Google Scholar
• Inman MD, Watson RM, Rerecich T, et al. Dose-dependent effects of inhaled mometasone furoate on airway function and inflammation after allergen inhalation challenge. Am J Respir Crit Care Med. 2001;164(4):569–574.
   PubMed Web of Science ®Google Scholar
• Oliver A, Bjermer L, Quinn D, et al. Modulation of allergen-induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination. Allergy. 2013;68(9):1136–1142.
   PubMed Web of Science ®Google Scholar
• Leigh R, Vethanayagam D, Yoshida M, et al. Effects of montelukast and budesonide on airway responses and airway inflammation in asthma. Am J Respir Crit Care Med. 2002;166(9):1212–1217.
   PubMed Web of Science ®Google Scholar
• Mata M, Sarriá B, Buenestado A, et al. Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells. Thorax. 2005;60(2):144–152.
   PubMed Web of Science ®Google Scholar
• Milara J, Morell A, Ballester B, et al. Roflumilast improves corticosteroid resistance COPD bronchial epithelial cells stimulated with toll like receptor 3 agonist. Respir Res. 2015;16:12.
   PubMed Web of Science ®Google Scholar
• Wenzel SE, Szefler SJ, Leung DY, et al. Bronchoscopic evaluation of severe asthma: persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med. 1997;156(3 Pt 1):737–743.
   PubMed Web of Science ®Google Scholar
• Loza MJ, Djukanovic R, Chung KF, et al. Validated and longitudinally stable asthma phenotypes based on cluster analysis of the ADEPT study. Respir Res. 2016;17(1):165.
   PubMedGoogle Scholar
• Fajt ML, Wenzel SE. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. J Allergy Clin Immunol. 2015;135(2): 299–310. quiz 311.
   PubMed Web of Science ®Google Scholar
• Lotvall J, Akdis CA, Bacharier LB, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol. 2011;127(2):355–360.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Tavakoli H, Lynd LD, et al. The impact of inappropriate use of short acting beta agonists in asthma. Respir Med. 2017;131:135–140.
   PubMed Web of Science ®Google Scholar
• Sulaiman I, Greene G, MacHale E, et al. A randomised clinical trial of feedback on inhaler adherence and technique in patients with severe uncontrolled asthma. Eur Respir J. 2018;51(1). pii: 1701126.
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med. 2018;378(20):1865–1876.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Reddel HK, O’Byrne PM, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med. 2018;378(20):1877–1887.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Cazzola M, Page CP, et al. Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. Pulm Pharmacol Ther. 2015;32:15–23.
   PubMed Web of Science ®Google Scholar